SCHEMBL4997577

SCHEMBL4997577

Fc1cc(-c2cncc(N3CCN(c4ccccc4F)CC3)n2)ccc1-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 3/20 0.53
CYP11B1 P15538 2/20 0.53
PIM2 Q9P1W9 9/20 0.48
PIM1 P11309 6/20 0.48
PIM3 Q86V86 5/20 0.48
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MAPT P10636 1/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43
CSNK2A2 P19784 1/20 0.42
CSNK2A1 P68400 1/20 0.42
FFAR4 Q5NUL3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4996129 0.88 CYP11B2 (0.55) CYP11B2CYP11B1PIM2PIM1PIM3
SCHEMBL4997575 0.85 CYP11B2 (0.52) CYP11B2CYP11B1PIM2PIM1PIM3
SCHEMBL5003024 0.85 CYP11B2 (0.52) CYP11B2CYP11B1PIM2PIM1PIM3
SCHEMBL5000701 0.85 LMNA (0.51) CYP11B2CYP11B1PIM2PIM1PIM3
SCHEMBL4994571 0.85 SMN1; SMN2 (0.51) CYP11B2CYP11B1PIM2PIM1PIM3
SCHEMBL4992191 0.83 MAPT (0.54) CYP11B2CYP11B1PIM2PIM1PIM3
SCHEMBL4992184 0.81 MAPT (0.52) CYP11B2CYP11B1PIM2PIM1PIM3
SCHEMBL4996845 0.81 MAPT (0.49) CYP11B2CYP11B1PIM2PIM1PIM3
SCHEMBL4997488 0.80 LMNA (0.50) CYP11B2CYP11B1PIM2LMNASMN1; SMN2
SCHEMBL5003397 0.79 SMN1; SMN2 (0.53) CYP11B2CYP11B1PIM2PIM1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194574-A1 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases AXXIMA PHARMACEUTICALS AG (DE) 2008-08-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194574-A1 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases PRNP, PSEN1, PPP5C CYP11B2 112/4885CYP11B1 132/4885PIM2 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.